Please ensure Javascript is enabled for purposes of website accessibility

No Surprise Here: Moderna's Revenue Skyrockets in Q4

By Keith Speights - Feb 25, 2021 at 9:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And it will soon soar even more thanks to the strong demand for Moderna's COVID-19 vaccine.

Moderna (MRNA -4.97%) has announced its financial results every quarter since going public in late 2018. But the biotech didn't have a product on the market during any of those updates. Until now.

The company reported its fourth-quarter results before the market opened on Thursday. For the first time, those results included product sales. Here are the highlights from Moderna's Q4 update.

COVID-19 vaccine vials and syringe on top of cash

Image source: Getty Images.

By the numbers

Moderna announced revenue of $570.7 million in the fourth quarter. In the prior-year period, the biotech's revenue totaled $14.1 million. The average analyst estimate projected Q4 revenue of $279.4 million.

The company posted a Q4 net loss of $272 million, or $0.69 per share, based on generally accepted accounting principles (GAAP). Moderna's net loss in the same period of 2019 was $123 million, or $0.37 per share. The Wall Street consensus was for a net loss of $0.35 per share.

Moderna ended the fourth quarter with cash, cash equivalents, and investments of $5.25 billion. This was a significant increase from the company's cash position of $1.26 billion as of Dec. 31, 2019.

Behind the numbers

As in the past, most of Moderna's revenue in the fourth quarter stemmed from grants. The company reported $341.4 million in grant revenue, much of this amount coming from an award from the Biomedical Advanced Research and Development Authority (BARDA). Another $29.5 million in revenue came from collaboration deals.

However, Moderna also reported product sales of $199.9 million in Q4 from COVID-19 vaccine mRNA-1273. It recognized revenue from the vaccine beginning in December 2020 after receiving U.S. and Canadian emergency use authorization (EUA).

Despite the enormous year-over-year revenue growth, Moderna's bottom line went in the wrong direction because of increased spending. Research and development expenses soared 543% to $759 million due primarily to mRNA-1273 clinical development and an inventory buildup before the U.S. EUA was issued. Selling, general, and administrative expenses more than tripled year over year to $79 million, mainly because of increased personnel costs and outside services.

Looking ahead

Some investors might have been concerned about Moderna's announcement earlier in February of a delay in manufacturing its COVID-19 vaccine doses. However, that's just a temporary issue. The company now expects to manufacture at least 700 million doses instead of a low estimate of 600 million doses this year, and has the potential to supply up to 1 billion doses.

Moderna shouldn't have any problems selling every dose it can make. The company has secured supply agreements so far for nearly 800 million doses. And that total doesn't include undisclosed volumes in its supply deals with Singapore and Qatar.

Could the biotech stock lose steam after this year? That doesn't appear likely. Moderna plans to increase its production capacity for mRNA-1273 to 1.4 billion doses in 2022 based on high demand for the vaccine. Assuming it sells all of those doses, Moderna stands to make even more money next year than it will in 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.